Penile cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:23:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Penile cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Use of Indocyanine Green and Technetium (99mTc) Nanocolloid for Sentinel Node Biopsy in Patients with Melanoma, Oral Cancer, or Penile Cancer https://clinicaltrials.eu/trial/study-on-the-use-of-indocyanine-green-and-technetium-99mtc-nanocolloid-for-sentinel-node-biopsy-in-patients-with-melanoma-oral-cancer-or-penile-cancer/ Wed, 29 Apr 2026 15:03:30 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-indocyanine-green-and-technetium-99mtc-nanocolloid-for-sentinel-node-biopsy-in-patients-with-melanoma-oral-cancer-or-penile-cancer/ This clinical trial is focused on patients with certain types of cancer, specifically melanoma of the head, neck, or upper part of the trunk, oral cancer, and penile cancer. The study is investigating a new method for identifying sentinel nodes, which are the first lymph nodes to which cancer cells are likely to spread from a primary tumor. The treatment being studied involves a combination of two substances: Indocyanine Green and Technetium (99mTc) Nanocolloid. These substances are used together as a hybrid tracer to help locate sentinel nodes during a procedure called a sentinel node biopsy.

The purpose of the study is to validate the effectiveness of this hybrid tracer in accurately identifying sentinel nodes. The study will compare the results of using the hybrid tracer with the standard method, which uses only Technetium (99mTc) Nanocolloid. Participants will receive an injection of the tracer substances, and imaging techniques such as lymphoscintigraphy and SPECT/CT will be used to visualize the sentinel nodes before surgery. The study aims to ensure that the hybrid tracer can reliably identify the same number of sentinel nodes as the standard method.

Throughout the study, researchers will monitor the number and intensity of the nodes detected by both the hybrid tracer and the standard method. This will help determine if the new method is as effective as the current standard in identifying sentinel nodes. The study is expected to provide valuable information that could improve the accuracy of sentinel node biopsies in patients with these types of cancer.

]]> Study on Using EMI-137 for Intraoperative Visualization in Patients with Penile and Tongue Cancer https://clinicaltrials.eu/trial/study-on-using-emi-137-for-intraoperative-visualization-in-patients-with-penile-and-tongue-cancer/ Wed, 29 Apr 2026 14:57:57 +0000 https://clinicaltrials.eu/trial/study-on-using-emi-137-for-intraoperative-visualization-in-patients-with-penile-and-tongue-cancer/ This clinical trial is focused on studying two types of cancer: penile cancer and tongue cancer. The treatment being tested is a new medication called EMI-137, which is a special type of protein linked to a dye. This medication is given as a powder that is mixed and then injected into the bloodstream. The purpose of the study is to see if this medication can help doctors see the cancer better during surgery by making the cancer cells light up.

During the study, patients who have either penile or tongue cancer and are scheduled for surgery will receive an injection of EMI-137. This medication is designed to attach to a specific part of the cancer cells called the c-Met receptor, which is often found in these types of cancers. When the medication attaches to the cancer cells, it makes them glow under a special light, helping surgeons to see the cancer more clearly during the operation.

The study will also look at whether this glowing effect can help identify cancer that has spread to nearby lymph nodes or detect early changes in the tissue that might turn into cancer. The results of the glowing effect will be compared to traditional methods used to study cancer cells in the lab. This research aims to improve the way surgeons can see and remove cancer during surgery, potentially leading to better outcomes for patients with penile and tongue cancer.

]]> Study on the Effects of Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin for Patients with Squamous Cell Carcinoma of the Penis and Lymph Node Metastasis https://clinicaltrials.eu/trial/study-on-the-effects-of-chemotherapy-with-paclitaxel-ifosfamide-and-cisplatin-for-patients-with-squamous-cell-carcinoma-of-the-penis-and-lymph-node-metastasis/ Wed, 29 Apr 2026 14:29:24 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-chemotherapy-with-paclitaxel-ifosfamide-and-cisplatin-for-patients-with-squamous-cell-carcinoma-of-the-penis-and-lymph-node-metastasis/ This clinical trial is focused on studying a type of cancer known as squamous cell carcinoma of the penis. The study is evaluating the effects of a combination of treatments, including surgery and chemotherapy, on the lymph nodes in the groin area. The chemotherapy treatment being tested is called TIP, which includes three medications: paclitaxel, ifosfamide, and cisplatin. These medications are given as a solution through a vein, known as intravenous infusion. The purpose of the study is to assess how well this combination of treatments works in preventing the cancer from coming back in the lymph nodes.

Participants in the study will receive the chemotherapy treatment along with a surgical procedure called lymphadenectomy, which involves removing lymph nodes from the groin area. The study will monitor the participants over a period of time to see if the cancer returns in the lymph nodes. Other medications, such as methylprednisolone, ranitidine, mesna, aprepitant, and dexchlorpheniramine maleate, may also be used to help manage side effects or support the main treatment. These medications are administered either orally or through injection.

The study aims to provide valuable information on the effectiveness of combining chemotherapy with surgery in treating this type of cancer. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the treatment’s impact on their health. The study is expected to continue until the end of 2027, with regular check-ups and assessments to track the progress of the treatment.

]]> Study on the Effectiveness of Carboplatin, Paclitaxel, and Pembrolizumab for Patients with Advanced Penile Cancer https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-carboplatin-paclitaxel-and-pembrolizumab-for-patients-with-advanced-penile-cancer/ Wed, 29 Apr 2026 14:29:15 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-carboplatin-paclitaxel-and-pembrolizumab-for-patients-with-advanced-penile-cancer/ This clinical trial is focused on studying the effectiveness of a treatment combination for locoregionally advanced penile cancer. The treatment involves three medications: pembrolizumab, also known by its code name MK-3475, paclitaxel, and carboplatin. These medications are given as solutions through an intravenous infusion, which means they are administered directly into the bloodstream through a vein.

The purpose of the study is to assess how well this combination of medications works in treating penile cancer that has spread to nearby areas. Participants in the study will receive the treatment over a period of time, and their response to the treatment will be monitored. The study aims to see if the cancer can be completely removed or reduced significantly. The trial will also look at the safety of the treatment and any side effects that may occur.

Throughout the study, participants will be closely observed to track their progress and any changes in their condition. The study will help researchers understand the potential benefits and risks of using this combination of medications for treating penile cancer. The findings from this study could provide valuable insights into new treatment options for this type of cancer.

]]> Study of TG4001 and Avelumab for Patients with Advanced HPV-16 Positive Cancers https://clinicaltrials.eu/trial/study-of-tg4001-and-avelumab-for-patients-with-advanced-hpv-16-positive-cancers/ Wed, 29 Apr 2026 14:27:14 +0000 https://clinicaltrials.eu/trial/study-of-tg4001-and-avelumab-for-patients-with-advanced-hpv-16-positive-cancers/ This clinical trial is focused on studying certain types of cancers that are linked to a virus called Human Papillomavirus (HPV), specifically the type known as HPV-16. The cancers being studied include those that can occur in areas such as the head and neck, cervix, vulva, vagina, penis, and anus. The study is testing a combination of two treatments: avelumab, which is a type of cancer immunotherapy, and TG4001, which is another form of immunotherapy designed to help the body’s immune system fight cancer cells.

The purpose of the study is to evaluate how safe and effective these treatments are when used together in patients with advanced stages of these HPV-16 related cancers. The study will be conducted in two phases. In the first phase, the focus will be on understanding the safety and how well patients tolerate the combination of avelumab and TG4001. In the second phase, the study will look at how well the combination works in terms of slowing down the progression of the cancer compared to using avelumab alone.

Participants in the study will receive the treatments through injections or infusions, and their health will be monitored over time to see how the cancer responds to the treatment. The study aims to provide valuable information on whether this combination of treatments can offer a new option for patients with these types of cancers.

]]>